Literature DB >> 31350930

Acute promyelocytic leukemia with a cryptic insertion of RARA into TBL1XR1.

Tomoo Osumi1,2, Akihiro Watanabe3, Kohji Okamura4, Kazuhiko Nakabayashi5, Masanori Yoshida1,6, Shin-Ichi Tsujimoto1,6, Meri Uchiyama1, Hiroyuki Takahashi7, Daisuke Tomizawa2, Kenichiro Hata5, Nobutaka Kiyokawa1, Motohiro Kato1,2.   

Abstract

Acute promyelocytic leukemia (APL) is cytogenetically characterized by the t(15;17) (q24;q21), although cases without this translocation exist. These cases are referred to as "cryptic" or "masked" translocations. Additionally, fewer than 5% of APL cases have another partner gene fused to the RARA gene. The TBL1XR1-RARA fusion gene has recently been reported as a novel RARA-associated fusion gene. We report a case with TBL1XR1-RARA and a masked translocation that was not detected by conventional tests for RARA-associated translocations. Three-year-old girl was diagnosed with APL based morphological findings, although conventional tests for RARA-associated chimeric genes were negative. She received all-trans retinoic acid treatment, but that was not effective. She achieved a complete remission (CR) by conventional multidrug chemotherapy, but had extramedullary relapse 2 years after onset. She underwent cord blood transplantation (CBT) in her second CR and is currently alive. To investigate the underlying pathogenesis of this unique case, we performed whole-genome sequencing and found a cryptic insertion of RARA gene into the TBL1XR1 gene. The transcript of the chimeric gene, TBL1XR1-RARA, was confirmed as an in-frame fusion by RT-PCR. In conclusion, we found using next-generation sequencing (NGS) a TBL1XR1-RARA fusion in a child with variant APL without the classic karyotype. Cryptic insertion could also occur in cases other than APL with PML-RARA. Variant APL has many variants and NGS analysis should therefore be considered for APL variant cases, even for those without RARA translocation detected by conventional analysis.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  TBL1XR1/RARA; acute promyelocytic leukemia; children; cryptic insertion

Mesh:

Substances:

Year:  2019        PMID: 31350930     DOI: 10.1002/gcc.22791

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

Review 1.  PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review.

Authors:  Marta Sobas; Maria Carme Talarn-Forcadell; David Martínez-Cuadrón; Lourdes Escoda; María J García-Pérez; Jose Mariz; María J Mela-Osorio; Isolda Fernández; Juan M Alonso-Domínguez; Javier Cornago-Navascués; Gabriela Rodríguez-Macias; María E Amutio; Carlos Rodríguez-Medina; Jordi Esteve; Agnieszka Sokół; Thais Murciano-Carrillo; María J Calasanz; Manuel Barrios; Eva Barragán; Miguel A Sanz; Pau Montesinos
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

2.  The expression and clinical significance of CD59 and FLAER in Chinese adult AML patients.

Authors:  Lijuan Li; Shunjie Yu; Shanshan Liu; Fanqiao Meng; Xiaotong Ren; Zhaoyun Liu; Rong Fu
Journal:  J Clin Lab Anal       Date:  2021-12-21       Impact factor: 2.352

Review 3.  Classic and Variants APLs, as Viewed from a Therapy Response.

Authors:  Marie-Claude Geoffroy; Hugues de Thé
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

Review 4.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

5.  Myeloid Sarcoma Type of Acute Promyelocytic Leukemia With a Cryptic Insertion of RARA Into FIP1L1: The Clinical Utility of NGS and Bioinformatic Analyses.

Authors:  Yongren Wang; Yaoyao Rui; Ying Shen; Jian Li; Poning Liu; Qin Lu; Yongjun Fang
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.